Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trial

INTRODUCTION: Proliferative diabetic retinopathy (PDR) is the main cause of severe visual loss in people with diabetes mellitus. The standard treatment for this condition is panretinal photocoagulation (PRP). This laser treatment is inherently destructive, with predictable adverse effects on visual...

Descripción completa

Detalles Bibliográficos
Autores principales: Sivaprasad, Sobha, Prevost, A Toby, Bainbridge, James, Edwards, Rhiannon Tudor, Hopkins, David, Kelly, Joanna, Luthert, Phil, Murphy, Caroline, Ramu, Jayashree, Sarafraz-Shekary, Negin, Vasconcelos, Joana, White-Alao, Beverley, Hykin, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Ophthalmology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4577925/
https://www.ncbi.nlm.nih.gov/pubmed/26369798
http://dx.doi.org/10.1136/bmjopen-2015-008405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4577925/
https://www.ncbi.nlm.nih.gov/pubmed/26369798
http://dx.doi.org/10.1136/bmjopen-2015-008405

Ejemplares similares